PMC:7160614 / 3351-4221 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"74","span":{"begin":0,"end":8},"obj":"Species"},{"id":"75","span":{"begin":575,"end":583},"obj":"Species"},{"id":"76","span":{"begin":835,"end":843},"obj":"Species"},{"id":"77","span":{"begin":14,"end":22},"obj":"Disease"},{"id":"78","span":{"begin":31,"end":40},"obj":"Disease"},{"id":"79","span":{"begin":69,"end":74},"obj":"Disease"},{"id":"80","span":{"begin":82,"end":87},"obj":"Disease"},{"id":"81","span":{"begin":99,"end":106},"obj":"Disease"},{"id":"82","span":{"begin":110,"end":117},"obj":"Disease"},{"id":"83","span":{"begin":311,"end":319},"obj":"Disease"},{"id":"84","span":{"begin":634,"end":642},"obj":"Disease"},{"id":"85","span":{"begin":703,"end":712},"obj":"Disease"},{"id":"86","span":{"begin":825,"end":834},"obj":"Disease"},{"id":"87","span":{"begin":861,"end":869},"obj":"Disease"}],"attributes":[{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"Tax:9606"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"Tax:9606"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"Tax:9606"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:C000657245"},{"id":"A78","pred":"tao:has_database_id","subj":"78","obj":"MESH:D011014"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"MESH:D005334"},{"id":"A80","pred":"tao:has_database_id","subj":"80","obj":"MESH:D003371"},{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"MESH:D063806"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"MESH:D005221"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"MESH:C000657245"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"MESH:C000657245"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"MESH:D011014"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:D011014"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Patients with COVID-19 develop pneumonia with associated symptoms of fever (98%), cough (76%), and myalgia or fatigue (44%) [3]. CT imaging plays a critical role in the diagnosis and the monitoring of disease progression [4–6]. The latest research studies described the characteristic imaging manifestations of COVID-19, including ground-glass opacities (GGO) (57 to 88%), bilateral involvement (76 to 88%), and peripheral distribution (33 to 85%) [7–10]. Other imaging features such as consolidation, cavitation, and interlobular septal thickening are also reported in some patients [11–13]. However, these imaging manifestations of COVID-19 are nonspecific and are difficult to distinguish from other pneumonia. To our knowledge, there have been no studies explicitly comparing imaging and clinical characteristics between pneumonia patients with and without COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T26","span":{"begin":14,"end":22},"obj":"Disease"},{"id":"T27","span":{"begin":31,"end":40},"obj":"Disease"},{"id":"T28","span":{"begin":311,"end":319},"obj":"Disease"},{"id":"T29","span":{"begin":634,"end":642},"obj":"Disease"},{"id":"T30","span":{"begin":703,"end":712},"obj":"Disease"},{"id":"T31","span":{"begin":825,"end":834},"obj":"Disease"},{"id":"T32","span":{"begin":861,"end":869},"obj":"Disease"}],"attributes":[{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Patients with COVID-19 develop pneumonia with associated symptoms of fever (98%), cough (76%), and myalgia or fatigue (44%) [3]. CT imaging plays a critical role in the diagnosis and the monitoring of disease progression [4–6]. The latest research studies described the characteristic imaging manifestations of COVID-19, including ground-glass opacities (GGO) (57 to 88%), bilateral involvement (76 to 88%), and peripheral distribution (33 to 85%) [7–10]. Other imaging features such as consolidation, cavitation, and interlobular septal thickening are also reported in some patients [11–13]. However, these imaging manifestations of COVID-19 are nonspecific and are difficult to distinguish from other pneumonia. To our knowledge, there have been no studies explicitly comparing imaging and clinical characteristics between pneumonia patients with and without COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T23","span":{"begin":146,"end":147},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T24","span":{"begin":585,"end":587},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"Patients with COVID-19 develop pneumonia with associated symptoms of fever (98%), cough (76%), and myalgia or fatigue (44%) [3]. CT imaging plays a critical role in the diagnosis and the monitoring of disease progression [4–6]. The latest research studies described the characteristic imaging manifestations of COVID-19, including ground-glass opacities (GGO) (57 to 88%), bilateral involvement (76 to 88%), and peripheral distribution (33 to 85%) [7–10]. Other imaging features such as consolidation, cavitation, and interlobular septal thickening are also reported in some patients [11–13]. However, these imaging manifestations of COVID-19 are nonspecific and are difficult to distinguish from other pneumonia. To our knowledge, there have been no studies explicitly comparing imaging and clinical characteristics between pneumonia patients with and without COVID-19."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":31,"end":40},"obj":"Phenotype"},{"id":"T6","span":{"begin":69,"end":74},"obj":"Phenotype"},{"id":"T7","span":{"begin":82,"end":87},"obj":"Phenotype"},{"id":"T8","span":{"begin":99,"end":106},"obj":"Phenotype"},{"id":"T9","span":{"begin":110,"end":117},"obj":"Phenotype"},{"id":"T10","span":{"begin":703,"end":712},"obj":"Phenotype"},{"id":"T11","span":{"begin":825,"end":834},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0003326"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0012378"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Patients with COVID-19 develop pneumonia with associated symptoms of fever (98%), cough (76%), and myalgia or fatigue (44%) [3]. CT imaging plays a critical role in the diagnosis and the monitoring of disease progression [4–6]. The latest research studies described the characteristic imaging manifestations of COVID-19, including ground-glass opacities (GGO) (57 to 88%), bilateral involvement (76 to 88%), and peripheral distribution (33 to 85%) [7–10]. Other imaging features such as consolidation, cavitation, and interlobular septal thickening are also reported in some patients [11–13]. However, these imaging manifestations of COVID-19 are nonspecific and are difficult to distinguish from other pneumonia. To our knowledge, there have been no studies explicitly comparing imaging and clinical characteristics between pneumonia patients with and without COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T32","span":{"begin":0,"end":128},"obj":"Sentence"},{"id":"T33","span":{"begin":129,"end":227},"obj":"Sentence"},{"id":"T34","span":{"begin":228,"end":455},"obj":"Sentence"},{"id":"T35","span":{"begin":456,"end":592},"obj":"Sentence"},{"id":"T36","span":{"begin":593,"end":713},"obj":"Sentence"},{"id":"T37","span":{"begin":714,"end":870},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Patients with COVID-19 develop pneumonia with associated symptoms of fever (98%), cough (76%), and myalgia or fatigue (44%) [3]. CT imaging plays a critical role in the diagnosis and the monitoring of disease progression [4–6]. The latest research studies described the characteristic imaging manifestations of COVID-19, including ground-glass opacities (GGO) (57 to 88%), bilateral involvement (76 to 88%), and peripheral distribution (33 to 85%) [7–10]. Other imaging features such as consolidation, cavitation, and interlobular septal thickening are also reported in some patients [11–13]. However, these imaging manifestations of COVID-19 are nonspecific and are difficult to distinguish from other pneumonia. To our knowledge, there have been no studies explicitly comparing imaging and clinical characteristics between pneumonia patients with and without COVID-19."}